Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

SFDA Approves China Medical’s HER2 FISH Probe

publication date: Nov 12, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Medical Technologies (中国医疗技术公司) received SFDA approval for its Breast Cancer HER2 FISH probe. Breast cancer patients are routinely tested for overexpression of HER2 protein because overexpression is associated with a higher incidence of recurrence and also predicts a better response to Genentech’s breast cancer drug, Herceptin. More details...

Stock Symbols: (NSDQ: CMED) (NYSE: DNA)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...